Pretransplant cardiovascular evaluation and posttransplant cardiovascular risk

Kidney International

Volumn 78, Issue SUPPL. 118, 2010, Pages

  Young, James B ^a   Neumayer, Hans Hellmut ^b   Gordon, Robert D ^c  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c CTI Clinical Trial and Consulting Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FLUINDOSTATIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ANEMIA; APPETITE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM EXAMINATION; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL; DEMOGRAPHY; DIABETES MELLITUS; DISEASE EXACERBATION; FATIGUE; GASTROINTESTINAL SYMPTOM; GRAFT SURVIVAL; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MORBIDITY; MORTALITY; NEPHROTOXICITY; OBESITY; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING; SIDE EFFECT;

ANEMIA; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HUMANS; HYPERCHOLESTEROLEMIA; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OBESITY; RISK FACTORS;

EID: 77955596732     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.209     Document Type: Review

References (82)

1. Hage FG, Venkataraman R, Zoghbi GJ et al. The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 2009; 53: 2129-2140.
2. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
3. de Jong PE, van der Velde M, Gansevoort RT et al. Screening for chronic kidney disease: where does Europe go? Clin J Am Soc Nephrol 2008; 3: 616-623.
4. Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12.
5. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047. (Pubitemid 350074801)
6. Cowie CC, Rust KF, Byrd-Holt DD et al. Prevalence of diabetes and impaired fasting glucose in adults in the US population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 2006; 29: 1263-1268.
7. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735-1743.
8. Culleton BF, Wilson PW. Cardiovascular disease: risk factors, secular trends, and therapeutic guidelines. J Am Soc Nephrol 1998; 9(12 Suppl): S5-S15.
9. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9(12 Suppl): S16-S23.
10. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1): S1-266.
11. Zoccali C. Renal impairment: a risk factor for ischemic heart disease. Curr Opin Pharmacol 2006; 6: 221-225.
12. Gibson CM, Pinto DS, Murphy SA et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 2003; 42: 1535-1543.
13. Hailpern SM, Cohen HW, Alderman MH. Renal dysfunction and ischemic heart disease mortality in a hypertensive population. J Hypertens 2005; 23: 1809-1816.
14. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75: 1291-1295.
15. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483.
16. Russo D, Corrao S, Miranda I et al. Progression of coronary artery calcification in predialysis patients. Am J Nephrol 2007; 27: 152-158.
17. Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol 2006; 1: 8-18.
18. Foley RN, Parfrey PS, Harnett JD et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192.
19. Pascual M, Theruvath T, Kawai T et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580-590. (Pubitemid 34438820)
20. Briganti EM, Russ GR, McNeil JJ et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347: 103-109.
21. Wheeler DC, Steiger J. Evolution and etiology of cardiovascular diseases in renal transplant recipients. Transplantation 2000; 70(11 Suppl): SS41-SS45.
22. West M, Sutherland DE, Matas AJ. Kidney transplant recipients who die with functioning grafts: serum creatinine level and cause of death. Transplantation 1996; 62: 1029-1030.
23. Ojo AO, Hanson JA, Wolfe RA et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307-313.
24. Prommool S, Jhangri GS, Cockfield SM et al. Time dependency of factors affecting renal allograft survival. J Am Soc Nephrol 2000; 11: 565-573.
25. Lindholm A, Albrechtsen D, Frodin L et al. Ischemic heart disease\major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60: 451-457.
26. Port FK, Wolfe RA, Mauger EA et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993; 270: 1339-1343.
27. Toussaint C, Kinnaert P, Vereerstraeten P. Late mortality and morbidity five to eighteen years after kidney transplantation. Transplantation 1988; 45: 554-558.
28. Kasiske BL. Ischemic heart disease after renal transplantation. Kidney Int 2002; 61: 356-369.
29. Sung RS, Althoen M, Howell TA et al. Peripheral vascular occlusive disease in renal transplant recipients: risk factors and impact on kidney allograft survival. Transplantation 2000; 70: 1049-1054.
30. USRDS 2007 annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2007.
31. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006; 82: 603-611.
32. Kidney disease: improving global outcomes (KDIGO) transplant work group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9(Suppl 3): S1-S155.
33. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
34. Kasiske BL, Anjum S, Shah R et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43: 1071-1081.
35. Opelz G, Zeier M, Laux G et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 2006; 17: 3257-3262.
36. Opelz G, Dohler B. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005; 5: 2725-2731.
37. Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024-2031.
38. Jardine AG, Holdaas H, Fellstrom B et al. fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am J Transplant 2004; 4: 988-995.
39. Holdaas H, Fellstrom B, Cole E et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005; 5: 2929-2936.
40. Friedman AN, Miskulin DC, Rosenberg IH et al. Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis 2003; 41: 480-487.
41. National Heart, Lung, and Blood Institute. The practical guide: Identification, evaluation, and treatment of overweight and obesity in adults. US Department of Health and Human Services Public Health Service, National Institutes of Health. In, Bethesda, MD, NIH 2000.
42. Gore JL, Pham PT, Danovitch GM et al. Obesity and outcome following renal transplantation. Am J Transplant 2006; 6: 357-363.
43. Lentine KL, Schnitzler MA, Abbott KC et al. De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications. Am J Kidney Dis 2005; 46: 720-733.
44. Aalten J, Christiaans MH, de Fijter H et al. The influence of obesity on short-and long-term graft and patient survival after renal transplantation. Transpl Int 2006; 19: 901-907.
45. Glanton CW, Kao TC, Cruess D et al. Impact of renal transplantation on survival in end-stage renal disease patients with elevated body mass index. Kidney Int 2003; 63: 647-653.
46. Meier-Kriesche HU, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation 2002; 73: 70-74.
47. Baum CL, Thielke K, Westin E et al. Predictors of weight gain and cardiovascular risk in a cohort of racially diverse kidney transplant recipients. Nutrition 2002; 18: 139-146.
48. Cosio FG, Falkenhain ME, Pesavento TE et al. Patient survival after renal transplantation: II. The impact of smoking. Clin Transplant 1999; 13: 336-341.
49. Kasiske BL, Klinger D. Cigarette smoking in renal transplant recipients. J Am Soc Nephrol 2000; 11: 753-759.
50. Santoro A. Anemia in renal insufficiency. Rev Clin Exp Hematol 2002; (Suppl 1): 12-20.
51. Vanrenterghem Y. Anemia after kidney transplantation. Transplantation 2009; 87: 1265-1267.
52. Ma JZ, Ebben J, Xia H et al. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10: 610-619. (Pubitemid 29117643)
53. Walker AM, Schneider G, Yeaw J et al. Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine. J Am Soc Nephrol 2006; 17: 2293-2298.
54. McCullough PA, Lepor NE. Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease. Rev Cardiovasc Med 2005; 6(Suppl 3): S4-12.
55. Rigatto C, Foley R, Jeffery J et al. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 2003; 14: 462-468.
56. Kadambi PV, Javaid B. Cardiovascular diseases in kidney transplant recipients: the role of anemia. Adv Chronic Kidney Dis 2004; 11: 328-333.
57. Wright J, Hutchison A. Cardiovascular disease in patients with chronic kidney disease. Vasc Health Risk Manag 2009; 5: 713-722.
58. Mark PB, Johnston N, Groenning BA et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 2006; 69: 1839-1845.
59. Farmer CK, Goldsmith DJ, Cox J et al. An investigation of the effect of advancing uraemia, renal replacement therapy and renal transplantation on blood pressure diurnal variability. Nephrol Dial Transplant 1997; 12: 2301-2307.
60. Silberberg J, Racine N, Barre P et al. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990; 6: 1-4.
61. Pascual J, Teruel JL, Moya JL et al. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol 1991; 35: 280-287.
62. Hernandez D. Left ventricular hypertrophy after renal transplantation: new approach to a deadly disorder. Nephrol Dial Transplant 2004; 19: 1682-1686.
63. El-Husseini AA, Sheashaa HA, Hassan NA et al. Echocardiographic changes and risk factors for left ventricular hypertrophy in children and adolescents after renal transplantation. Pediatr Transplant 2004; 8: 249-254.
64. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S et al. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1992-1997.
65. Fernandez-Fresnedo G, Escallada R, Rodrigo E et al. Proteinuria is an independent risk factor of cardiovascular disease in renal transplant patient. Transplant Proc 2002; 34: 367. (Pubitemid 34311714)
66. Lim HS, Blann AD, Chong AY et al. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care 2004; 27: 2918-2924.
67. Chauveau P, Chadefaux B, Coude M et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int Suppl 1993; 41: S72-S77.
68. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 2002; 325: 1202.
69. Abedini S, Holme I, Marz W et al. Inflammation in renal transplantation. Clin J Am Soc Nephrol 2009; 4: 1246-1254.
70. Zoccali C. Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. Kidney Int 2006; 70: 26-33.
71. Stuveling EM, Hillege HL, Bakker SJ et al. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 2003; 63: 654-661.
72. Pilmore H. Cardiac assessment for renal transplantation. Am J Transplant 2006; 6: 659-665.
73. Kasiske BL, Cangro CB, Hariharan S et al. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 2001; 1(Suppl 2): 3-95.
74. Gaston RS, Danovitch GM, Adams PL et al. The report of a national conference on the wait list for kidney transplantation. Am J Transplant 2003; 3: 775-785.
75. Sharma R, Pellerin D, Gaze DC et al. Dobutamine stress echocardiography and the resting but not exercise electrocardiograph predict severe coronary artery disease in renal transplant candidates. Nephrol Dial Transplant 2005; 20: 2207-2214. (Pubitemid 41510099)
76. Rabbat CG, Treleaven DJ, Russell JD et al. Prognostic value of myocardial perfusion studies in patients with end-stage renal disease assessed for kidney or kidney-pancreas transplantation: a meta-analysis. J Am Soc Nephrol 2003; 14: 431-439.
77. Group TVACABSCS. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. N Engl J Med 1984; 311: 1333-1339.
78. Herzog CA, Ma JZ, Collins AJ. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 2002; 106: 2207-2211.
79. Herzog CA, Ma JZ, Collins AJ. Long-term outcome of dialysis patients in the United States with coronary revascularization procedures. Kidney Int 1999; 56: 324-332.
80. Marcen R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009; 69: 2227-2243.
81. Verdecchia P, Staessen JA, Angeli F et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009; 374: 525-533.
82. Goldsmith D, Pietrangeli CE. The metabolic syndrome following kidney transplantation. kidney Int 2010; 78(Suppl 118): S8-S14